000154791 001__ 154791
000154791 005__ 20240229123112.0
000154791 0247_ $$2doi$$a10.1038/s41408-020-0323-4
000154791 0247_ $$2pmid$$apmid:32404891
000154791 0247_ $$2altmetric$$aaltmetric:82089480
000154791 037__ $$aDKFZ-2020-01029
000154791 041__ $$aeng
000154791 082__ $$a610
000154791 1001_ $$0P:(DE-HGF)0$$aPulte, Dianne$$b0$$eFirst author
000154791 245__ $$aChanges in long term survival after diagnosis with common hematologic malignancies in the early 21st century.
000154791 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2020
000154791 3367_ $$2DRIVER$$aarticle
000154791 3367_ $$2DataCite$$aOutput Types/Journal article
000154791 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600853209_25390
000154791 3367_ $$2BibTeX$$aARTICLE
000154791 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154791 3367_ $$00$$2EndNote$$aJournal Article
000154791 500__ $$a#EA:C070#LA:C070#
000154791 520__ $$aFive-year survival has increased for many hematologic malignancies in the 21st century. However, whether this has translated into greater long-term survival is unknown. Here, we examine 10- and 20-year survival for patients with multiple myeloma (MM), acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), chronic lymphoid leukemia (CLL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). Data were extracted from the Surveillance, Epidemiology, and End Results-9 database. Patients age 15+ with the above malignancies were included. The newly developed boomerang method was used to examine 10- and 20-year relative survival (RS) for patients in 2002-2006 and 2012-16. Ten and 20-year RS increased for each malignancy examined, with increases ranging from +4.4% units for 20-year RS for AML to +23.1% units for 10-year RS for CML. Ten year RS was >50% in 2012-16 for patients with CLL, CML, HL, NHL, and DLBCL, at 77.1%, 62.1%, 63.9%, 64.5%, and 63.0%, respectively. Survival dropped between 10 and 20 years after diagnosis for most malignancies. Long-term survival is increasing for common hematologic malignancies, but late mortality is an ongoing issue. Further study of long-term outcomes in curable malignancies to determine the reason for these later decreases in survival is indicated.
000154791 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000154791 588__ $$aDataset connected to CrossRef, PubMed,
000154791 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1
000154791 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b2$$eLast author
000154791 773__ $$0PERI:(DE-600)2600560-8$$a10.1038/s41408-020-0323-4$$gVol. 10, no. 5, p. 56$$n5$$p56$$tBlood cancer journal$$v10$$x2044-5385$$y2020
000154791 909CO $$ooai:inrepo02.dkfz.de:154791$$pVDB
000154791 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000154791 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000154791 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000154791 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000154791 9141_ $$y2020
000154791 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD CANCER J : 2017
000154791 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154791 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154791 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154791 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000154791 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000154791 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000154791 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000154791 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000154791 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154791 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154791 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154791 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000154791 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000154791 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBLOOD CANCER J : 2017
000154791 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000154791 9202_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000154791 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000154791 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000154791 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000154791 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000154791 980__ $$ajournal
000154791 980__ $$aVDB
000154791 980__ $$aI:(DE-He78)C070-20160331
000154791 980__ $$aI:(DE-He78)C120-20160331
000154791 980__ $$aI:(DE-He78)HD01-20160331
000154791 980__ $$aUNRESTRICTED